TY - JOUR
T1 - Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas
AU - Meric, Funda
AU - Milas, Mira
AU - Hunt, Kelly K.
AU - Hess, Kenneth R.
AU - Pisters, Peter W.T.
AU - Hildebrandt, Gerhard
AU - Patel, Shreyaskumar R.
AU - Benjamin, Robert S.
AU - Plager, Carl
AU - Papadopolous, Nicholas E.J.
AU - Burgess, Michael A.
AU - Pollock, Raphael E.
AU - Feig, Barry W.
PY - 2000/10/1
Y1 - 2000/10/1
N2 - Purpose: The purpose of this study was to test the hypothesis that neoadjuvant chemotherapy (NeoCT) does not increase morbidity in patients undergoing radical surgery for soft tissue sarcomas. Patients and Methods: The records of 309 patients who presented to The University of Texas M.D. Anderson Cancer Center for definitive surgical management of primary soft tissue sarcomas were retrospectively reviewed. One hundred five patients who received NeoCT were compared with 204 patients who had surgery first (Surg). Patients had extremity sarcomas (71 NeoCT patients and 130 Surg patients) or retroperitoneal/visceral sarcomas (34 NeoCT and 74 Surg). Results: NeoCT patients had larger tumors (median, 12 v 8 cm), more frequently had high-grade tumors (90% v 64%), and were younger (median age 47 v 55 years). The incidence of surgical complications was not different for NeoCT patients than for Surg patients, both in those with extremity sarcomas (34% v 41%) and in those with retroperitoneal/visceral sarcomas (29% v 34%). The most common complications were wound infections and other wound complications. Preoperative radiation therapy, autologous flap coverage, and extremity tumors were associated with increased wound complications. No significant differences in length of hospital stay, rate of readmission, or rate of reoperation for complications were found between the NeoCT and Surg groups. One of the three postoperative deaths in our series occurred in the NeoCT group. Conclusion: In this retrospective review, there was no evidence that NeoCT increased postoperative morbidity in patients with soft tissue sarcomas. Prospective, randomized studies are needed to confirm these results. (C) 2000 by American Society of Clinical Oncology.
AB - Purpose: The purpose of this study was to test the hypothesis that neoadjuvant chemotherapy (NeoCT) does not increase morbidity in patients undergoing radical surgery for soft tissue sarcomas. Patients and Methods: The records of 309 patients who presented to The University of Texas M.D. Anderson Cancer Center for definitive surgical management of primary soft tissue sarcomas were retrospectively reviewed. One hundred five patients who received NeoCT were compared with 204 patients who had surgery first (Surg). Patients had extremity sarcomas (71 NeoCT patients and 130 Surg patients) or retroperitoneal/visceral sarcomas (34 NeoCT and 74 Surg). Results: NeoCT patients had larger tumors (median, 12 v 8 cm), more frequently had high-grade tumors (90% v 64%), and were younger (median age 47 v 55 years). The incidence of surgical complications was not different for NeoCT patients than for Surg patients, both in those with extremity sarcomas (34% v 41%) and in those with retroperitoneal/visceral sarcomas (29% v 34%). The most common complications were wound infections and other wound complications. Preoperative radiation therapy, autologous flap coverage, and extremity tumors were associated with increased wound complications. No significant differences in length of hospital stay, rate of readmission, or rate of reoperation for complications were found between the NeoCT and Surg groups. One of the three postoperative deaths in our series occurred in the NeoCT group. Conclusion: In this retrospective review, there was no evidence that NeoCT increased postoperative morbidity in patients with soft tissue sarcomas. Prospective, randomized studies are needed to confirm these results. (C) 2000 by American Society of Clinical Oncology.
UR - http://www.scopus.com/inward/record.url?scp=0034306320&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034306320&partnerID=8YFLogxK
U2 - 10.1200/JCO.2000.18.19.3378
DO - 10.1200/JCO.2000.18.19.3378
M3 - Article
C2 - 11013278
AN - SCOPUS:0034306320
SN - 0732-183X
VL - 18
SP - 3378
EP - 3383
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 19
ER -